id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC10472990
core_pubmed_pmc
The effects of orally administered trazodone on ambulation and recumbency in healthy horses
The effects of orally administered trazodone on ambulation and recumbency in healthy horses Abstract Abstract Background Trazodone, a serotonin receptor antagonist and reuptake inhibitor, might be a useful adjunctive treatment in the initial management of horses with acute laminitis if it minimizes ambulation or encour...
PMC3944114
core_pubmed_pmc
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients Abstract Abstract Tobramycin powder for inhalation (TOBI Podhaler or TIP) is approved for the treatment of Pseudomonas aeruginosa airway infection in patients with cystic fibrosis (CF). A population pharmacokinetic model for tobramycin...
PMC10981932
core_pubmed_pmc
Improvement of Charcot-Marie-Tooth Phenotype with a Nanocomplex Treatment in Two Transgenic Models of CMT1A
Improvement of Charcot-Marie-Tooth Phenotype with a Nanocomplex Treatment in Two Transgenic Models of CMT1A Abstract Abstract Curcumin has been shown to exert beneficial effects in peripheral neuropathies. Despite its known biological activities, curcumin has unfavorable pharmacokinetics. Its instability has been linke...
PMC8779621
core_pubmed_pmc
Topical Drug Delivery to the Posterior Segment of the Eye
Topical Drug Delivery to the Posterior Segment of the Eye Abstract Abstract Topical drug delivery to the posterior segment of the eye is a very complex challenge. However, topical delivery is highly desired, to achieve an easy-to-use treatment option for retinal diseases. In this review, we focus on the drug characteri...
PMC10637048
core_pubmed_pmc
Improving combination therapies: targeting A 2B -adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression
Improving combination therapies: targeting A 2B -adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression Abstract Abstract Background We investigated the role of A 2B -adenosine receptor in regulating immunosuppressive metabolic stress in the tumor microenvironment. Novel A 2B -adenosine r...
PMC6521995
core_pubmed_pmc
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children Abstract Background To access the long term relationship between efavirenz plasma concentrations and evolution of HIV RNA loads and CD4 cell counts in children. Methods Retrospective analysis of data fro...
PMC9641010
core_pubmed_pmc
Allometric-like scaling of AAV gene therapy for systemic protein delivery
Allometric-like scaling of AAV gene therapy for systemic protein delivery Abstract The use of adeno-associated virus (AAV) as a gene delivery vehicle for secreted peptide therapeutics can enable a new approach to durably manage chronic protein insufficiencies in patients. Yet, dosing of AAVs have been largely empirical...
PMC12715039
core_pubmed_pmc
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy Abstract Abstract Background and Objectives The use of the 12-dose, once-weekly, rifapentine-based (3HP), short-course tuberculosis preventive tre...
PMC10470178
core_pubmed_pmc
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV Abstract Summary Background Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigat...
PMC3619141
core_pubmed_pmc
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population Abstract Abstract Risperidone non-compliance is often high due to undesirable side effects, whose development is in part genetically determined. Studies with genetic variants involved in the pharmacokinetics and...
PMC12728298
core_pubmed_pmc
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis Abstract Abstract Background In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium...
PMC12332264
core_pubmed_pmc
Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial
Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial Abstract Abstract Objective To evaluate the similarity of BAT2606 and mepolizumab, including pharmacokinetic profile...
PMC11782957
core_pubmed_pmc
Comparative study on the bioavailability and bioequivalence of rifapentine capsules in humans
Comparative study on the bioavailability and bioequivalence of rifapentine capsules in humans Abstract Introduction : Rifapentine, a potent semi-synthetic member of the rifamycin class, is approved for the treatment of tuberculosis due to its effective bactericidal properties. It is essential to assess the bioequivalen...
PMC10648862
core_pubmed_pmc
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects Abstract ABSTRACT Contezolid acefosamil (also known as MRX-4), a prodrug of contezolid, is under development for treatment of multidrug-resistant Gram-positive...
PMC6337661
core_pubmed_pmc
Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan
Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan Abstract Abstract Several basic pharmacokinetic and pharmacological studies were conducted as part of a group of studies to clarify the drug-drug interaction (DDI) between memantine (MEM), a drug used to treat ...
PMC8876625
core_pubmed_pmc
In Vitro–In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier
In Vitro–In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier Abstract Abstract Static in vitro permeation experiments are commonly used to gain insights into the permeation properties of drug substances but exhibit limitations due to missing physiologic ...
PMC11466922
core_pubmed_pmc
Anesthetic management of a patient with mandibular hypoplasia, deafness, progeroid features, lipodystrophy syndrome: a case report
Anesthetic management of a patient with mandibular hypoplasia, deafness, progeroid features, lipodystrophy syndrome: a case report Abstract Abstract Background Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy (MDPL) syndrome is a rare autosomal dominant disorder that presents unique challenges for...
PMC9392571
core_pubmed_pmc
Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats
Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats Abstract Abstract Objective(s): Diabetes mellitus (DM) affects the pharmacokinetics of drugs. Ranolazine is an antianginal drug that is prescribed in DM patients with angina. We decided to evaluate the effect of DM on the phar...
PMC9826033
core_pubmed_pmc
A novel transdermal ketoprofen formulation for analgesia in cattle
A novel transdermal ketoprofen formulation for analgesia in cattle Abstract Abstract Ketoprofen is registered in many countries for injectable administration in cattle. Because it is soluble in a wide range of excipients, development of a novel transdermal (TD) ketoprofen formulation was pursued to provide a convenient...
PMC9919154
core_pubmed_pmc
The Quantification of Paclitaxel and Its Two Major Metabolites in Biological Samples by HPLC-MS/MS and Its Application in a Pharmacokinetic and Tumor Distribution Study in Xenograft Nude Mouse
The Quantification of Paclitaxel and Its Two Major Metabolites in Biological Samples by HPLC-MS/MS and Its Application in a Pharmacokinetic and Tumor Distribution Study in Xenograft Nude Mouse Abstract Abstract A rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) method was...
PMC2861020
core_pubmed_pmc
Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics
Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics Abstract Abstract Background Concurrent chemoradiation with 5-fluorouracil (5-FU) is widely accepted for treatment of abdominal malignancy. Nonetheless, the interactions between radiation and 5-FU remain unclear. We evaluated the influence of abdominal irr...
PMC6822801
core_pubmed_pmc
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population Abstract Abstract Introduction Major depressive disorder (MDD) is associated with a significant burden of disease in China. Awareness and better access to treatments could help alleviate the burden associated with MDD. Because variations have been ob...
PMC12095442
core_pubmed_pmc
Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model
Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model Abstract Abstract The aim of the analysis was to develop a phenomenological longitudinal population pharmacokinetics (PK)-anti-drug antibodies (ADA) mo...
PMC8149336
core_pubmed_pmc
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report Abstract Background Enzalutamide is an orally administered drug that blocks signaling in the androgen receptor with clinical activity in both chemotherapy–naive and post-...
PMC8036287
core_pubmed_pmc
Recent Developments in Nanomedicine for Pediatric Cancer
Recent Developments in Nanomedicine for Pediatric Cancer Abstract Abstract Cancer is the second biggest cause of death in children in the US. With the development of chemotherapy, there has been a substantial increase in the overall survival rate in the last 30 years. However, the overall mortality rate in children wit...
PMC9482091
core_pubmed_pmc
In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism
In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism Abstract Hypercoagulability is frequently observed in patients with severe coronavirus disease-2019 (COVID-19). Platelets are a favorable target for effectively treating hypercoagulability in COVI...
PMC7954971
core_pubmed_pmc
Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy
Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy Abstract Abstract Oral amoxicillin/clavulanate is a community workhorse antibiotic, routinely prescribed for respiratory tract infections, skin infections as well as urinary tract infections (UTIs). Multiple adult and paediatric dose formul...
PMC9826446
core_pubmed_pmc
In Vitro and In Vivo Pharmacological Profiles of DS‐1211, a Novel Potent, Selective, and Orally Bioavailable Tissue‐Nonspecific Alkaline Phosphatase Inhibitor
In Vitro and In Vivo Pharmacological Profiles of DS‐1211, a Novel Potent, Selective, and Orally Bioavailable Tissue‐Nonspecific Alkaline Phosphatase Inhibitor Abstract ABSTRACT Inhibition of tissue‐nonspecific alkaline phosphatase (TNAP) may prevent ectopic soft tissue calcification by increasing endogenous pyrophospha...
PMC5991273
core_pubmed_pmc
Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel
Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel Abstract Abstract Background: A simple and sensitive reversed-phase high-performanc...
PMC8561294
core_pubmed_pmc
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways Abstract Abstract Intravenous iron-carbohydrate complex preparations (IVIP) are noninterchangeable pro-drugs: their pharmacokinetics (PK) varies determined by semi-crystalline iron core and carbohydrate shell struct...
PMC10937790
core_pubmed_pmc
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation Abstract Purpose A series of iterative population pharmacokinetic (PK) modeling and probability of target attainment (PTA) analyses based on emerging data supported dose selection for aztreonam-avi...
PMC6735221
core_pubmed_pmc
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours Abstract Abstract Background Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. Methods This dose-findi...
PMC6130628
core_pubmed_pmc
Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats
Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats Abstract Abstract Context: Salvianolic acid A (Sal A) is a hydrophilic bioactive compound isolated from Salvia miltiorrhiza Bunge (Lamiaceae). It exerts beneficial effects after oral administration on diabetic compli...
PMC9963605
core_pubmed_pmc
Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study
Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study Abstract Abstract (1) Background: this article investigates which PK metrics in a single-dose study (concentration at the end of posology interval, C τ , partial areas under the...
PMC5720757
core_pubmed_pmc
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis Abstract We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence. This study ...
PMC7150726
core_pubmed_pmc
Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application Abstract Abstract In our research, a straightforward UPLC-MS/MS method, with diazepam as the internal standard (IS), was proposed and acknowledged to determine the concentrations of enasiden...
PMC8975757
core_pubmed_pmc
Population Pharmacokinetic Analysis to Assist Dose Selection of the l -Ornithine Salt of Phenylacetic Acid
Population Pharmacokinetic Analysis to Assist Dose Selection of the l -Ornithine Salt of Phenylacetic Acid Abstract Background and Objective l -Ornithine phenylacetate is an intravenous formulation of the l -ornithine salt of phenylacetic acid under development for the treatment of hepatic encephalopathy. Very limited ...
PMC11047043
core_pubmed_pmc
Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses ( Equus caballus )
Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses ( Equus caballus ) Abstract The pharmacokinetics and tolerability of cannabinoids and their metabolites were determined in eight horses after enteral administration of a commercial CBD/CBDA-rich hemp oil prod...
PMC10341764
core_pubmed_pmc
Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511 : Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice
Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511 : Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice Abstract Cholesterol is essential for cellular function and is stored as cholesteryl esters (CEs). CEs biosy...
PMC10324051
core_pubmed_pmc
Quantification of Biologically Active DNA Alkylation in Temozolomide-Exposed Glioblastoma Cell Lines by Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry: Method Development and Recommendations for Validation
Quantification of Biologically Active DNA Alkylation in Temozolomide-Exposed Glioblastoma Cell Lines by Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry: Method Development and Recommendations for Validation Abstract Abstract Quantitative monitoring of biologically active methylations of guanines in sam...
PMC5749554
core_pubmed_pmc
The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation
The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation Abstract Epiberberine (EPI) is a novel and potentially effective therapeutic and preventive agent for diabetes and cardiovascular disease. To evaluate its potential value for drug developmen...
PMC5098533
core_pubmed_pmc
Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold
Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold Abstract Abstract Malaria disease continues to be a major health problem worldwide due to the emergence of multidrug-resistant strains of Plasmodium falciparum . In recent...
PMC12125103
core_pubmed_pmc
The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial
The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial Abstract This study aimed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of SHR6508 inject...
PMC9354257
core_pubmed_pmc
Population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency undergoing hematopoietic stem cell transplantation
Population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency undergoing hematopoietic stem cell transplantation Abstract Abstract The present study aimed to explore the population pharmacokinetics and initial dose optimization of tacrolimus in children with s...
PMC3290802
core_pubmed_pmc
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults Abstract Abstract We investigated the effect of food on the steady-state pharmacokinetics of a proprietary fixed-dose combination (FDC) tablet containing tenofovir disoproxil fumarate (TDF)/emtricitabine/...
PMC5723705
core_pubmed_pmc
Identification of an antibody‐based immunoassay for measuring direct target binding of RIPK 1 inhibitors in cells and tissues
Identification of an antibody‐based immunoassay for measuring direct target binding of RIPK 1 inhibitors in cells and tissues Abstract Abstract Therapies that suppress RIPK 1 kinase activity are emerging as promising therapeutic agents for the treatment of multiple inflammatory disorders. The ability to directly measur...
PMC6137745
core_pubmed_pmc
Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial Abstract Abstract Background Coronary heart disease (CHD) is a common cardiovascular disease accounting for 10–20% mortality by heart disease worl...
PMC11907281
core_pubmed_pmc
Hallmarks of Polymersome Characterization
Hallmarks of Polymersome Characterization Abstract Abstract Polymersomes have the potential to become the next generation of vesicular drug delivery systems. Their high chemical versatility and in certain cases higher membrane stability than liposomes raised the high hopes for polymersomes as a drug carrier, but the cl...
PMC4554395
core_pubmed_pmc
Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection
Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection Abstract Background Paclitaxel (PTX) solid lipid nanoparticles (SLNs) modified with 2-hydroxypropyl-β-cyclodextrin (HPCD) were evaluated fo...
PMC6161197
core_pubmed_pmc
Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment
Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment Abstract Abstract The aim of the study was the evaluation of the suitability of 5-oxo-2-pyrrolidinecarboxylic acid (PCA), also in combination with hyaluronic acid (HA), as artificial tears for treatment of...
PMC7076376
core_pubmed_pmc
Self-Microemulsifying Drug Delivery System of Phillygenin: Formulation Development, Characterization and Pharmacokinetic Evaluation
Self-Microemulsifying Drug Delivery System of Phillygenin: Formulation Development, Characterization and Pharmacokinetic Evaluation Abstract Abstract Phillygenin, as an active ingredient of Forsythia suspensa , possesses a wide range of biological and pharmacological activity. However, its development and application a...
PMC6425913
core_pubmed_pmc
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome Abstract Abstract Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithro...
PMC9328191
core_pubmed_pmc
An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia
An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia Abstract Aims The aim of this study was to characterize the pharmacokinetic/pharmacodynamic relationships of cortisol and the adrenal biomarkers 17‐hydroxyprogesterone and...
PMC3389237
core_pubmed_pmc
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency Abstract Abstract Introduction An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. Methods P...
PMC8078810
core_pubmed_pmc
Genistein as a dietary supplement; formulation, analysis and pharmacokinetics study
Genistein as a dietary supplement; formulation, analysis and pharmacokinetics study Abstract Abstract The objective of this study is to improve and optimize the formulation of Genistein in capsules in order to result in a better pharmacokinetic profile comparing to existing commercial products. In order to do this, fiv...
PMC7694782
core_pubmed_pmc
Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease Abstract Abstract Amikacin is used as a therapy for patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) who are resistant to macrolide antibiotics or have ...
PMC6978620
core_pubmed_pmc
Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study
Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study Abstract Abstract Dihydromyricetin (DHM) is a natural dihydroflavonol compound with quite a number of important pharmacological properties. However, its low solubility in water and poor stability in...
PMC4461960
core_pubmed_pmc
Pharmacophore modeling, in silico screening, molecular docking and molecular dynamics approaches for potential alpha-delta bungarotoxin-4 inhibitors discovery
Pharmacophore modeling, in silico screening, molecular docking and molecular dynamics approaches for potential alpha-delta bungarotoxin-4 inhibitors discovery Abstract Background: The alpha-delta bungartoxin-4 (α-δ-Bgt-4) is a potent neurotoxin produced by highly venomous snake species, Bungarus caeruleus, mainly targe...
PMC3170612
core_pubmed_pmc
Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer Abstract Background Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet...
PMC11052786
core_pubmed_pmc
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study Abstract Abstract Background and Objective During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protec...
PMC11488524
core_pubmed_pmc
A First-Passage Model of Intravitreal Drug Delivery and Residence Time—Influence of Ocular Geometry, Individual Variability, and Injection Location
A First-Passage Model of Intravitreal Drug Delivery and Residence Time—Influence of Ocular Geometry, Individual Variability, and Injection Location Abstract Abstract Purpose Standard of care for various retinal diseases involves recurrent intravitreal injections. This motivates mathematical modeling efforts to identify...
PMC12642005
core_pubmed_pmc
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders Abstract Abstract Background/Objectives: Type 2 diabetes and obesity present escalating global health and economic challenges, highlighting the need for therapies that can eff...
PMC10534564
core_pubmed_pmc
Pharmacoinformatics and Breed-Based De Novo Hybridization Studies to Develop New Neuraminidase Inhibitors as Potential Anti-Influenza Agents
Pharmacoinformatics and Breed-Based De Novo Hybridization Studies to Develop New Neuraminidase Inhibitors as Potential Anti-Influenza Agents Abstract Abstract Influenza represents a profoundly transmissible viral ailment primarily afflicting the respiratory system. Neuraminidase inhibitors constitute a class of antivir...
PMC11659749
core_pubmed_pmc
Rational design and synthesis of novel phenyltriazole derivatives targeting MRSA cell wall biosynthesis †
Rational design and synthesis of novel phenyltriazole derivatives targeting MRSA cell wall biosynthesis † Abstract Abstract Antimicrobial resistance in methicillin-resistant Staphylococcus aureus (MRSA) is a major global health challenge. This study reports the design and synthesis of novel phenyltriazole derivatives a...
PMC6910856
core_pubmed_pmc
Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples
Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples Abstract Abstract Although 90% of BRD relapses are reported to receive retreatment with a different class of anti...
PMC7416317
core_pubmed_pmc
Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids
Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids Abstract Abstract The assessment of potentially sensitive populations is an important application of risk assessment. To address the concern for age-related sensitivity to pyrethroid insecticides, life-stage physiologically b...
PMC9007597
core_pubmed_pmc
Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma
Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma Abstract Abstract Avelumab is an anti–PD‐L1 monoclonal antibody approved as monotherapy for Merkel cell carcinoma (MCC) and urothelial carcinoma (UC), and in combination with axitinib...
PMC12240918
core_pubmed_pmc
A Mechanistic Physiologically Based Pharmacokinetic (PBPK) modeling approach for fexofenadine: predictive pharmacokinetic insights in humans
A Mechanistic Physiologically Based Pharmacokinetic (PBPK) modeling approach for fexofenadine: predictive pharmacokinetic insights in humans Abstract Abstract The physiologically based pharmacokinetic (PBPK) modeling is an in-silico technique that determines drug pharmacokinetics (PK) by considering blood circulation a...
PMC10295470
core_pubmed_pmc
Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study
Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study Abstract Purpose Ibuprofen is the first of the nonsteroidal anti-inflammatory drug (NSAID) to be used in the clinic. Our aim was to explore the p...
PMC10653426
core_pubmed_pmc
Computational exploration of novel ROCK2 inhibitors for cardiovascular disease management; insights from high-throughput virtual screening, molecular docking, DFT and MD simulation
Computational exploration of novel ROCK2 inhibitors for cardiovascular disease management; insights from high-throughput virtual screening, molecular docking, DFT and MD simulation Abstract Cardiovascular disorders are the world’s major cause of death nowadays. To treat cardiovascular diseases especially coronary arter...
PMC8835974
core_pubmed_pmc
Clinical Breakpoint of Apramycin to Swine Salmonell a and Its Effect on Ileum Flora
Clinical Breakpoint of Apramycin to Swine Salmonell a and Its Effect on Ileum Flora Abstract The purpose of this study was to establish the clinical breakpoint (CBP) of apramycin (APR) against Salmonella in swine and evaluate its effect on intestinal microbiota. The CBP was established based on three cutoff values of w...
PMC5433037
core_pubmed_pmc
Evaluation of dosing strategy for pembrolizumab for oncology indications
Evaluation of dosing strategy for pembrolizumab for oncology indications Abstract Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizum...
PMC10715210
core_pubmed_pmc
Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa Abstract ABSTRACT The objective of this study was to examine the relationship between colistin plasma concentrations and clinical outcomes in patients with...
PMC5694418
core_pubmed_pmc
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s Abstract Objective The objective of this study was to determine the magnitude of drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (BOC) and antiretroviral...
PMC5867502
core_pubmed_pmc
Pediatric Melanoma and Drug Development
Pediatric Melanoma and Drug Development Abstract Importance—Pediatric melanoma occurs, albeit rarely. Should patients be treated by today’s medical standards, or be subjected to medically unnecessary clinical studies? Observations—We identified international, industry-sponsored pediatric melanoma studies triggered by r...
PMC9293673
core_pubmed_pmc
Biological fate and interaction with cytochromes P450 of the nanocarrier material, d - α -tocopheryl polyethylene glycol 1000 succinate
Biological fate and interaction with cytochromes P450 of the nanocarrier material, d - α -tocopheryl polyethylene glycol 1000 succinate Abstract d - α -Tocopheryl polyethylene glycol 1000 succinate (TPGS, also known as vitamin E-TPGS) is a biodegradable amphiphilic polymer prepared by esterification of vitamin E with p...
PMC10820132
core_pubmed_pmc
PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses
PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses Abstract Abstract This study aimed to develop a physiologically based pharmacokinetic (PBPK) model that simulates metabolically cleared compounds’ pharmacokinetics (PK) in pregnant subjects and fetuses. This m...
PMC3805522
core_pubmed_pmc
Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines Abstract Abstract The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive...
PMC12900388
core_pubmed_pmc
Killing of Coccidioides by drugs
Killing of Coccidioides by drugs Abstract Abstract Coccidioidomycosis has long been regarded as one of the most difficult mycoses to eradicate in patients with progressive infection. There are few published studies of inhibition of Coccidioides in vitro , comparing the results with various drugs as measured by minimal ...
PMC10141864
core_pubmed_pmc
An Experimental and Computational Analysis of Plant Compounds from Whole Urtica dioica L. Plant’s Essential Oil for Antioxidant and Antibacterial Activities
An Experimental and Computational Analysis of Plant Compounds from Whole Urtica dioica L. Plant’s Essential Oil for Antioxidant and Antibacterial Activities Abstract Abstract As the Urtica dioica L. whole plant’s essential oil has presented significant multiple activities, it was therefore evaluated using the GC–MS tec...
PMC4693565
core_pubmed_pmc
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation Abstract Aim The aim of the present study was to evaluate the pharmacokinetics of bevacizumab and various dosing strategies for this agent in paediatric patients. Methods Data were collected f...
PMC7692360
core_pubmed_pmc
A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults
A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults Abstract Abstract A universal pharmacokinetic model was developed from pooled paediatric and adult data (40.6 postmenstrual weeks, 70.8 years, 3.1–152 kg). A three-compartment pharmacokinetic model with first-order elimination was superior to ...
PMC7011682
core_pubmed_pmc
Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles
Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles Abstract Background Recombinant human keratinocyte growth factor (rHuKGF) has gained considerable attention by researchers as epithelial cells proliferating agent...
PMC4488495
core_pubmed_pmc
Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema
Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema Abstract Abstract Hereditary angioedema (HAE), a rare autosomal dominant genetic disorder, is caused by a deficiency in functional C1 esterase inhibitor (C1-INH). This potentially life-threatening condition manifests as recurrent attacks...
PMC4145439
core_pubmed_pmc
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study Abstract Abstract Objectives The aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 mono...
PMC6021620
core_pubmed_pmc
Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults
Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults Abstract ABSTRACT There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus-infected (HIV + ) ind...
PMC4559583
core_pubmed_pmc
A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows
A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows Abstract Background and Objective Chronic diseases are associated with pathophysiological changes that cou...
PMC4426134
core_pubmed_pmc
The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide
The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide Abstract The study aimed to examine the effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite, paracetamol glucuronide. Both drugs share metabolic pathways...
PMC10945216
core_pubmed_pmc
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome Abstract Abstract Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)3...
PMC8592511
core_pubmed_pmc
ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations
ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations Abstract Abstract ModVizPop is an interactive and dynamic visualization tool developed for simulating differential equation–based population pharmacokinetic (PK) and pharmacodynamic (PD) models with vari...
PMC12292558
core_pubmed_pmc
Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo‐Controlled, Parallel Group, First‐In‐Human Study in Healthy Male Participants
Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo‐Controlled, Parallel Group, First‐In‐Human Study in Healthy Male Participants Abstract ABSTRACT BI 1839100 is a selective antagonist of transient receptor potential ankyrin 1 (TRPA1). Topically applied TR...
PMC12971858
core_pubmed_pmc
Assessing the impact of bacterial heterogeneity on bacteriophage population dynamics
Assessing the impact of bacterial heterogeneity on bacteriophage population dynamics Abstract Abstract Bacteriophages follow complex replication dynamics in codependence with their host cells. The corresponding dynamics are usually described with three key parameters: the adsorption rate , the burst size and the latent...
PMC12882745
core_pubmed_pmc
Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease
Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease Abstract Axatilimab, a monoclonal antibody targeting colony‐stimulating factor 1 (CSF‐1) receptor, is approved in the US for the treatment of chronic graft‐versus‐host disease (cGVHD) after failure of ≥2 lines of systemi...
PMC12352948
core_pubmed_pmc
Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries
Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries Abstract SUMMARY BACKGROUND Rifampicin-resistant TB (RR-TB) in children is frequently treated with clofazimine (CFZ), widely available as a 100mg gel capsule. This formulation is challenging to administer and i...
PMC8787557
core_pubmed_pmc
Novel antifungal agents in clinical trials
Novel antifungal agents in clinical trials Abstract Abstract Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The ...
PMC10145228
core_pubmed_pmc
Deep Learning Methods Applied to Drug Concentration Prediction of Olanzapine
Deep Learning Methods Applied to Drug Concentration Prediction of Olanzapine Abstract Abstract Pharmacometrics and the utilization of population pharmacokinetics play an integral role in model-informed drug discovery and development (MIDD). Recently, there has been a growth in the application of deep learning approache...
PMC5644278
core_pubmed_pmc
First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Abstract Introduction Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have...
PMC10301000
core_pubmed_pmc
Nobiletin with AIEE Characteristics for Targeting Mitochondria and Real-Time Dynamic Tracking in Zebrafish
Nobiletin with AIEE Characteristics for Targeting Mitochondria and Real-Time Dynamic Tracking in Zebrafish Abstract Abstract Nobiletin is a natural product with multiple physiological activities and is the main ingredient of Pericarpium Citri Reticulatae . We successfully discovered that nobiletin exhibits aggregation ...
PMC4594082
core_pubmed_pmc
The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors
The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors Abstract Background Heartburn and other symptoms of gastro-oesophageal reflux occur in ~30 % of survey respondents in multiple countries worldwide. Heartburn and acid regurgitation are common complaints in the pharmacy, where...
PMC11469207
core_pubmed_pmc
In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs
In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs Abstract Abstract The favorable properties of antimicrobial peptides (AMPs) to rapidly kill pathogens are often limited by unfavorable pharmacokinetics due to fast degradation and renal clearance rates. Here, a prodrug strategy linking pro...